期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乙型肝炎和丙型肝炎的抗病毒治疗进展 被引量：2

下载PDF
导出
摘要 第59届美国肝病年会于2008年10月31日-11月04日在美国旧金山召开，约有来自世界各地的8000名代表参加了会议。会议共收录论文摘要1980篇，共有大会和分会报告280多个，内容涉及到病毒性肝炎、肝硬化、肝细胞癌、自身免疫性肝病、肝衰竭、脂肪肝、遗传性肝脏代谢疾病等各种肝病的临床和基础研究，本文重点概述乙型肝炎和丙型肝炎抗病毒治疗方面的研究进展。
作者 徐东平
机构地区 解放军传染病研究所
出处 《传染病信息》 2008年第6期321-323,共3页 Infectious Disease Information
关键词 抗病毒治疗 丙型肝炎 乙型肝炎 自身免疫性肝病 肝脏代谢疾病 病毒性肝炎 论文摘要 肝细胞癌
分类号 R512.62 [医药卫生—内科学] R512.63 [医药卫生—内科学]
  • 相关文献

参考文献12

  • 1Heathcote E J, Gane E J, deMan RA, et al. Two year tenofovir disproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis[J]. Hepatology, 2008,48(4 Suppl):S376.
  • 2Fung SK, Mazzulli T, Sherman M ,et al. Presence of rta194T at baseline does not reduce efficacy to tenofovir (TDF) in patients with lamivudine (LAM)-resistant chronic hepatitis B[J]. Hepatology, 2008,48(4 Suppl):S699.
  • 3Brunetto M, Cavallone D, Moriconi F, et al. Kinetics of HBsag decline during and following treatment of CHB: early and rapid HBsAg decline during peginterferon alpa-2a is predictive of HBsAg clearance [J]. Hepatology, 2008,48 (4 Suppl):S717.
  • 4Nguyen MH ,Trinh HN,Garcia RT,et al. Treatment outcomes in patients with chronic hepatitis B (CHB) and partial response to adefovir (ADV) who were switched to entecavir (ETV)[J]. Hepatology, 2008,48(4 Suppl):S711.
  • 5徐东平,周先志.丙型肝炎抗病毒治疗药物研究进展[J].传染病信息,2008,21(4):210-213. 被引量：15
  • 6Lawita E J, Sulkowski MS, Jacobson IM, et al. Satety, tolerability and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3/4A protease,in patients with chronic HCV genotype 1 infection[J]. Hepatology, 2008,48(4 Suppl):S403.
  • 7Lin TI, Devogelaere B, Lenz O, et al. Inhibitory activity of TMC435350 on HCV NS3/4A proteases from genotypes 1 to 6[J]. Hepatology, 2008,48(4 Suppl):S 1166.
  • 8Steffy K, Kirkovsky L, Lanford R, et al. Antiviral efficacy of the HCV RNA potymerase inhibitor ANA598 in the chimpanzee model of HCV infection[J]. Hepatology, 2008,48(4 Suppl):S1163.
  • 9Xu D, Zhou Z, Wang L, et al. Uneven geographic distribution of HCV genotypes and higher prevalence of co-infection with more than one HCV genotype in blood donors in China[J]. Hepatology, 2008,48(4 Suppl):S 1128.
  • 10Howell CD, Huang C, Bryson LC, et al. Gene transcription profile links hepatic fibrosis and virologic response to peginterferon plus ribavirin treatment for HCV genotype 1[J]. Hepatology, 2008,48(4 Suppl):S355.

二级参考文献26

  • 1Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wildtype and resistant genotype 1 hepatitis C virus replication in patients[J]. Hepatology,2007,46(3):631-639.
  • 2Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders[J]. Gastroenterology, 2007,132(4): 1270-1278.
  • 3Anonymous. Combination therapy with HCV protease inhibitor boceprevir produces a high rate of early virological response in genotype 1 hepatitis C patients[EB/OL].[2008- 01-09 ]. http ://www. hivandh epatitis. com/hep_c/news/2007/102307_a.html.
  • 4Baker R. Experimental Roche polymerase inhibitor R1626 shows robust synergistic effect in combination with pegylated interferon with or without ribavirin[C/OL]//58th Annual Meeting of the American Association for the Study of Liver Diseases,Boston,USA,November 2-6,2007. [2008-01-07].http : //www. hivandhepatitis. com/2007icr/aasld/docs/110607_b. html.
  • 5Kaita K, Yoshida E, Kunimoto D, et al. Phase Ⅱ proof of concept study of celgosivir in combination with peginterferon alf a-2b and ribavirin in chronic hepatitis C genotype 1 nonresponder patients[C/OL]//42nd Meeting of the European Association for the Study of Liver Diseases,Barcelona, Spain, April 11-15, 2007.[2008 -01-09]. http://www.natap.org/2007/ EASL/EASL_61.htm.
  • 6Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection [J]. Lancet Infect Dis,2005,5(9): 558-567.
  • 7Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes[J]. Hepatology,2005,42(4):962-973.
  • 8Nakano T, Lu L, He Y, et al. Population genetic history of hepatitis C virus lb infection in China[J]. J Gen Virol,2006, 87(Pt 1):73-82.
  • 9Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update[J]. Ann Pharmacother,2006,40(1): 74-82.
  • 10Kemmer N, Neff GW.Managing chronic hepatitis C in the diffficuh-to-treat patient[J]. Liver Int,2007,27 (10):1297- 1310.

共引文献14

同被引文献22

引证文献2

二级引证文献26

传染病信息
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部